Neha serves as the chief financial officer (CFO) and chief business officer (CBO) at Latigo Biotherapeutics, bringing more than 15 years of experience in healthcare investment banking, and financial and strategic leadership. Neha most recently served as CFO and executive vice president (EVP) of corporate development at Artiva Biotherapeutics, a publicly traded clinical-stage company developing off-the-shelf NK cell therapy for autoimmune disease, where she led financial operations, business development, and investor relations and communications functions, including its transition to a public company and $179 million initial public offering.

Prior to Artiva, Neha served as the CFO and EVP of corporate development at Kinnate Biopharma, a clinical-stage precision oncology company, where she led the company’s financial operations, business development, and investor relations and communications functions. She played a lead role in Kinnate’s exploration of strategic alternatives, which resulted in a successful asset sale to Pierre Fabre Laboratories and the sale of Kinnate to XOMA Corporation.

Earlier in her career, Neha was a vice president in the Healthcare Investment Banking Group and a member of the Mergers and Acquisitions (M&A) Group within the Investment Banking Division at Goldman Sachs. While at Goldman Sachs, she established herself as a senior leader in the healthcare coverage group, working with a variety of biopharmaceutical boards and management teams on a broad range of strategic financial matters, executing financings as well as leading M&A transactions.

Neha has successfully executed more than $100 billion in transactions in the biopharmaceutical, medical technology, and tools and diagnostics sectors. Neha is currently on the board of Arcutis Biotherapeutics, serving as a member of their audit committee. She holds a B.S.E. in biomedical engineering and economics from Duke University.